Overcoming FTD-activated ERK/AKT/STAT3 signaling provides a compelling rationale for testing and optimizing the combination strategy with TAS102 plus regorafenib against metastatic colorectal cancer [8]. The gene discussed is AKT1; the disease is metastatic colorectal cancer.